The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.50
Bid: 63.00
Ask: 66.00
Change: 1.00 (1.57%)
Spread: 3.00 (4.762%)
Open: 63.00
High: 66.50
Low: 61.50
Prev. Close: 63.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM & Board Changes

29 Jun 2023 11:04

RNS Number : 3975E
NetScientific PLC
29 June 2023
 

For immediate release

NetScientific plc

("NetScientific", "Group" or the "Company")

Result of Annual General Meeting and Board Changes

NetScientific plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that all resolutions set out in the 2023 Notice of Annual General Meeting sent to shareholders were duly passed at the Company's Annual General Meeting held earlier today.

Result of Annual General Meeting

Resolutions 1 to 9 were passed as Ordinary Resolutions and Resolution 10 was passed as a Special Resolution. The proxy voting results are as follows:

 

Resolution

For

%

Against

%

Vote Total

Vote Total as % of Issued Share Capital

Withheld*

1. To receive and adopt the Company's Annual Report and Accounts for the period ended 31 December 2022

6,910,987

100%

686

0%

6,911,673

29%

-

2. To receive and approve the Directors' Remuneration Report

6,871,686

99%

39,975

1%

6,911,661

29%

12

3. To reappoint BDO LLP as auditors for the forthcoming year

6,873,987

99%

37,686

1%

6,911,673

29%

-

4. To authorise Audit Committee in determining Auditors' remuneration

6,910,987

100%

686

0%

6,911,673

29%

-

5. To confirm the reappointment of Dr Ilian Iliev as a director

6,905,598

100%

6,075

0%

6,911,673

29%

-

6. To confirm the reappointment of Edward Hooper as a director

6,905,598

100%

6,075

0%

6,911,673

29%

-

7. To confirm the reappointment of Dr Jonathan Robinson as a director

6,905,598

100%

6,075

0%

6,911,673

29%

-

8. To confirm the reappointment of Dr Charles Spicer as a director

6,897,104

100%

6,075

0%

6,903,179

29%

8,494

9. To authorise the Directors to allot relevant securities pursuant to section 551 of the Companies Act 2006

6,865,004

99%

46,669

1%

6,911,673

29%

-

10. To disapply pre-emption rights on the allotment of securities or sale of treasury shares in connection with a pre-emptive offer or on allotment of shares

6,810,004

99%

101,669

1%

6,911,673

29%

-

 

* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

Board Changes

Further to the announcement made on 3 April 2023, Prof Stephen Smith has retired from the NetScientific Board with effect from the closing of the AGM. It is anticipated that he will remain an adviser to a number of the Group's life sciences portfolio companies.

Further to the announcement made on 31 May 2023, Dr Charles Spicer has taken over as Chair with effect from the closing of the AGM. Dr Jonathan Robinson has retired as Interim Chair and moves to the role of Senior Independent Director.

Dr Ilian Iliev, Chief Executive Officer of the Company, commented:

"On behalf of the Company and the Board, I extend a warm welcome to Charles as he joins our team. We are looking forward to working with him and benefiting from his expertise. Additionally, I would like to express my appreciation to Prof. Stephen Smith for his dedicated service since 2016. We greatly value his ongoing counsel and understanding of the life sciences sector. Finally, I would like to extend my gratitude to Jonathan Robinson for his interim board leadership. We look forward to continuing to work alongside him in his new role as Senior Independent Director."

Dr Charles Spicer, Chair of the Company, commented:

"I am excited by the future prospects of the Company and eagerly anticipate working with Ilian and the wider team. Our primary objective will be to drive shareholder returns through profitable exits and strategic expansion of our portfolio."

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific plc (AIM: NSCI) is deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGCGDLCUDDGXC
Date   Source Headline
4th Nov 20217:00 amRNSSofant Signs EUR7.3m ESA Contract
1st Nov 20212:16 pmRNSPDS to License Novel Proteins for Flu Vaccine
26th Oct 20217:00 amRNSEMV Capital Participates in £843k Sofant Funding
22nd Oct 202111:18 amRNSProAxsis announces the approval of a key US patent
22nd Oct 20219:04 amRNSHolding(s) in Company
21st Oct 20214:40 pmRNSSecond Price Monitoring Extn
21st Oct 20214:35 pmRNSPrice Monitoring Extension
21st Oct 20212:17 pmRNSPDS Phase 2 Clinical Trial Update
5th Oct 20217:00 amRNSPDS Phase 2 Clinical Trial Update
4th Oct 20217:00 amRNSInvestor Presentations
30th Sep 202110:22 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSGrant of Options to Directors
29th Sep 20217:00 amRNSInterim Results
20th Sep 20217:00 amRNSNotice of Results and Analyst Briefing
16th Sep 20217:00 amRNSInvestment in Martlet Capital Limited
9th Aug 20215:59 pmRNSHolding(s) in Company
30th Jul 20219:12 amRNSHolding(s) in Company
26th Jul 20214:25 pmRNSHolding(s) in Company
22nd Jul 20214:29 pmRNSHolding(s) in Company
20th Jul 20212:05 pmRNSSecond Price Monitoring Extn
20th Jul 20212:00 pmRNSPrice Monitoring Extension
16th Jul 202110:35 amRNSDirector/PDMR Shareholding
1st Jul 202112:08 pmRNSHolding(s) in Company
30th Jun 20213:42 pmRNSHolding(s) in Company
30th Jun 202110:29 amRNSHolding(s) in Company
30th Jun 202110:27 amRNSHolding(s) in Company
28th Jun 20213:18 pmRNSResult of General Meeting, TVR & PDMR Dealings
22nd Jun 20217:00 amRNSPDS Announces Closing of c. $52m Public Offering
16th Jun 20217:00 amRNSNSCI Participates in $45m PDS Equity Issue
15th Jun 20217:00 amRNSPDS announces proposed offering of common stock
10th Jun 202112:56 pmRNSResult of Placing and Total Voting Rights
10th Jun 20217:00 amRNSProposed Placing
9th Jun 20214:40 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension
8th Jun 20214:36 pmRNSPrice Monitoring Extension
8th Jun 20211:40 pmRNSPDS Announces Release of PDS0101 Interim Data
8th Jun 202111:05 amRNSSecond Price Monitoring Extn
8th Jun 202111:00 amRNSPrice Monitoring Extension
7th Jun 20214:40 pmRNSSecond Price Monitoring Extn
7th Jun 20214:35 pmRNSPrice Monitoring Extension
7th Jun 20212:06 pmRNSSecond Price Monitoring Extn
7th Jun 20212:00 pmRNSPrice Monitoring Extension
7th Jun 20217:00 amRNSProAxsis Update
3rd Jun 20214:30 pmRNSResult of AGM
3rd Jun 20218:14 amRNSHolding(s) in Company
28th May 20212:20 pmRNSHolding(s) in Company
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.